...
首页> 外文期刊>Thrombosis Research: An International Journal on Vascular Obstruction, Hemorrhage and Hemostasis >Combination of P2Y12 reaction unit and percentage of platelet inhibition assessed by VerifyNow P2Y12 assay is a useful predictor of long-term clinical outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention
【24h】

Combination of P2Y12 reaction unit and percentage of platelet inhibition assessed by VerifyNow P2Y12 assay is a useful predictor of long-term clinical outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention

机译:verifynow p2y12测定评估的P2Y12反应单位和血小板抑制百分比是急性冠状动脉综合征患者经皮冠状动脉介入的患者长期临床结果的有用预测因素

获取原文
获取原文并翻译 | 示例
           

摘要

Introduction: High on-treatment platelet reactivity is a well-known risk factor for adverse events in patients undergoing percutaneous coronary intervention (PCI). This study was to investigate the value of a novel platelet reactivity-based system, named the COP-INH (COmbination of P2Y12 reaction unit [ PRU] and percentage of platelet inhibition [% INH]), assessed by VerifyNow P2Y12 assay, for predicting the long-term ischaemic events in patients with acute coronary syndrome (ACS) undergoing PCI.
机译:介绍:高治疗血小板反应性是经皮冠状动脉介入(PCI)的患者不良事件的众所周知的风险因素。 该研究是研究通过VIREDNOW P2Y12测定评估的COP-INH(P2Y12反应单位[PRU]的组合和血小板抑制[%INH]的百分比)的基于新型血小板反应性的系统的价值,用于预测 急性冠状动脉综合征(ACS)接受PCI患者的长期缺血事件。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号